Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors, Including Checkpoint Inhibitor Naïve Participants With Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors

NCT07262619 is registered in ClinicalTrials.gov with Eikon Therapeutics as lead sponsor.

NCT NCT07262619
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07262619 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors, Including Checkpoint Inhibitor Naïve Participants With Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors
Lead sponsor
Eikon Therapeutics
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 20, 2026
Completion date
March 31, 2029
Enrollment
160 (estimated)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, endometrial cancer, mismatch repair deficient or msi-high solid tumors, msi-h or dmmr advanced solid tumors, msi-h/dmmr colorectal cancer, msi-h/dmmr gastric cancer, msi-h/dmmr gastroesophageal-junction cancer